Pituitary imaging using a labelled somatostatin analogue in acromegaly.

Pituitary imaging using a labelled somatostatin analogue in acromegaly.

OBJECTIVE: A number of neoplasms are known to express somatostatin receptors, and the use of somatostatin receptor imaging in their localization has recently been described. We have looked at the use of an 123I-labelled Tyr3-octreotide analogue of somatostatin in the visualization and functional cha...

Full description

Bibliographic Details
Main Authors:	Ur, E, Mather, S, Bomanji, J, Ellison, D, Britton, K, Grossman, AB, Wass, J, Besser, G
Format:	Journal article
Language:	English
Published:	1992

Similar Items

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
by: Ur, E, et al.
Published: (1993)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
by: King, C, et al.
Published: (1993)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
by: Jenkins, P, et al.
Published: (2000)

Acromegaly: Treatment with somatostatin analogs
by: Karavitaki, N, et al.
Published: (2005)

A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
by: Bomanji, J, et al.
Published: (1992)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
by: Chahal, H, et al.
Published: (2010)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
by: Chahal, H, et al.
Published: (2011)

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
by: Karavitaki, N, et al.
Published: (2005)

Antiangiogenic effects of somatostatin analogues.
by: García de la Torre, N, et al.
Published: (2002)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
by: Grossman, A, et al.
Published: (1985)

Depot-bromocriptine treatment for prolactinomas and acromegaly.
by: Grossman, A, et al.
Published: (1986)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
by: Hubina, E, et al.
Published: (2006)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Acromegaly, colonic polyps and carcinoma.
by: Jenkins, P, et al.
Published: (1997)

The pathology of median neuropathy in acromegaly.
by: Jenkins, P, et al.
Published: (2000)

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
by: Karavitaki, N, et al.
Published: (2008)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
by: Kaltsas, G, et al.
Published: (2005)

PITUITARY-ADRENAL RESPONSE TO CRF UNALTERED BY SOMATOSTATIN IN NORMAL SUBJECTS
by: Kopelman, P, et al.
Published: (1988)

The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects.
by: Stafford, P, et al.
Published: (1989)

The effect of enkephalin analogue on pituitary hormone release in human obesity.
by: Finer, N, et al.
Published: (1987)

New treatments for acromegaly.
by: Wass, J, et al.
Published: (1998)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
by: Cakir, M, et al.
Published: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
by: Cakir, M, et al.
Published: (2010)

Uterine leiomyomata in women with acromegaly
by: Kaltsas, G, et al.
Published: (2000)

Acromegaly: Beyond surgery.
by: Thanabalasingham, G, et al.
Published: (2013)

Two synchronous pituitary adenomas causing Cushing's Disease and acromegaly
by: Schorr, M, et al.
Published: (2019)

Combined use of vasopressin and synthetic hypothalamic releasing factors as test of anterior pituitary function.
by: Grossman, A, et al.
Published: (1986)

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)
by: Giustina, A, et al.
Published: (2024)

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
by: Sheaves, R, et al.
Published: (1996)

Evidence for the effectiveness of radiotherapy in the treatment of acromegaly.
by: Wass, J
Published: (1997)

Long-term effects of radiotherapy for acromegaly.
by: Wass, J
Published: (1996)

Radiotherapy in acromegaly: a protagonists viewpoint.
by: Wass, J
Published: (2003)

Menstrual irregularity in women with acromegaly.
by: Kaltsas, G, et al.
Published: (1999)

Conventional Pituitary Irradiation Is Effective in Lowering Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly
by: Jenkins, P, et al.
Published: (2006)

Investigation protocol: acromegaly and its investigation.
by: Duncan, E, et al.
Published: (1999)

Guidelines for acromegaly management.
by: Melmed, S, et al.
Published: (2002)

Second brain tumour after treatment for pituitary adenoma.
by: Wass, J, et al.
Published: (1992)

Abnormal growth hormone release in response to human pancreatic growth hormone releasing factor in acromegaly.
by: Besser, G, et al.
Published: (1983)

An analogue of met-enkephalin attenuates the pituitary-adrenal response to ovine corticotrophin releasing factor.
by: Grossman, A, et al.
Published: (1986)